Clinical Trial Update: A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status. [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 dose-dense regimen using Doxil (liposomal doxorubicin) with CDOP/rituximab for patients with diffuse large B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Rituxan (rituximab)

Snippet

Sponsor: The Alvin and Lois Lapidus Cancer Institute | Conditions: Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin | Phase 2 | Status: UNKNOWN